07Jul 2023
Pembrolizumab‐associated chronic rhinosinusitis: A new endotype and management considerations

Pembrolizumab‐associated chronic rhinosinusitis: A new endotype and management considerations

A recent study has found that patients undergoing treatment with pembrolizumab, a medication used for cancer immunotherapy, may experience an increase in inflammation in their paranasal sinuses. However, there is a potential treatment option available for these patients. Researchers have discovered that the use of topical triamcinolone in carboxymethylcellulose can effectively alleviate the inflammation in the sinuses. This finding provides a promising solution for managing the side effects of pembrolizumab treatment, offering relief for patients dealing with sinus inflammation as a result of their immunotherapy.

  • #ent

Like

Save

Share